EUVIMEDOpdag EUVIMED
Crossref

Biomaterial-Based Lymphangiogenesis-Enhanced Therapeutic Strategy for Robustly-Integrated Medication-Related Osteonecrosis of Jaw Prevention

Zhiwei Cao, Chengzhi Zhao, Liru Hu, Fuli Peng, Zhanhong Liu, Xiao Yang, Jian Pan

ACS Applied Materials & Interfaces · 2025

DOI: 10.1021/acsami.5c02812 ↗

At a glance

Journal article in ACS Applied Materials & Interfaces, 2025. Written by Zhiwei Cao and 6 co-authors. Institution: State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases, Department of Oral and…. Major MEDLINE topics: Lymphangiogenesis, Zoledronic Acid, Insulin-Like Growth Factor I, Bisphosphonate-Associated Osteonecrosis of the Jaw. Cited 11 times so far (Crossref); 87 references. Funded by: West China School of Stomatology, Sichuan University, National Key Research and Development Program of China, Health Commission of Sichuan Province.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse effect associated with antiresorptive drugs, including bisphosphonates (BPs), and its pathogenesis remains unclear. The incidence of MRONJ is increasing; however, effective preventive strategies remain limited, and few studies have investigated the application of biomaterials for its prevention. In this study, we first demonstrated that zoledronic acid (ZA) suppresses the PI3K/AKT signaling pathway in endothelial cells, a key regulator of angiogenesis and lymphangiogenesis, while simultaneously inducing apoptosis. Building on this finding, we established a rat model of MRONJ-like lesions to examine vascular and lymphatic alterations during disease progression. This model exhibited a marked impairment of angiogenesis and lymphangiogenesis in both the extraction sockets and the surrounding soft tissues. Insulin-like growth factor (IGF-1), a known pathway PI3K/AKT agonist, was subsequently introduced and shown to restore the pathway activity and enhance endothelial cell function in vitro. To further explore its therapeutic potential, we developed an IGF-1-loaded hydrogel for localized administration in an MRONJ prevention model. This hydrogel significantly promoted angiogenesis and lymphangiogenesis and successfully prevented the onset of MRONJ-like lesions in rats. These findings suggest that PI3K/AKT pathway suppression underlies BP-induced vascular and lymphatic dysfunction and that IGF-1 delivered via a straightforward hydrogel system offers a promising strategy for MRONJ prevention.

Subjects

MeSH terms (MEDLINE)

LymphangiogenesisZoledronic AcidInsulin-Like Growth Factor IBisphosphonate-Associated Osteonecrosis of the JawBiocompatible MaterialsHydrogelsAnimalsRatsRats, Sprague-DawleyHumansPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktMaleSignal TransductionHuman Umbilical Vein Endothelial Cells

Author keywords

Medication-Related Osteonecrosis of the JawPI3K/AKT signaling pathwayangiogenesischitosan/gelatin/β-glycerol phosphate hydrogelinsulin-like growth factorlymphangiogenesis

Substances

Zoledronic AcidInsulin-Like Growth Factor IBiocompatible MaterialsHydrogelsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-akt

Authors and institutions

  • State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases, Department of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan Un…
  • National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610064, Sichuan China.

Funding

  • West China School of Stomatology, Sichuan University
  • National Key Research and Development Program of China
  • Health Commission of Sichuan Province
  • Science and Technology Department of Sichuan Province

Cite

APA

Cao, Z., Zhao, C., Hu, L., Peng, F., Liu, Z., Yang, X., & Pan, J. (2025). Biomaterial-Based Lymphangiogenesis-Enhanced Therapeutic Strategy for Robustly-Integrated Medication-Related Osteonecrosis of Jaw Prevention. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.5c02812

Vancouver

Cao Z, Zhao C, Hu L, Peng F, Liu Z, Yang X, et al. Biomaterial-Based Lymphangiogenesis-Enhanced Therapeutic Strategy for Robustly-Integrated Medication-Related Osteonecrosis of Jaw Prevention. ACS Applied Materials & Interfaces. 2025. doi:10.1021/acsami.5c02812

BibTeX
@article{Cao2025,
  author = {Cao, Zhiwei and Zhao, Chengzhi and Hu, Liru and Peng, Fuli and Liu, Zhanhong and Yang, Xiao and Pan, Jian},
  title = {Biomaterial-Based Lymphangiogenesis-Enhanced Therapeutic Strategy for Robustly-Integrated Medication-Related Osteonecrosis of Jaw Prevention},
  journal = {ACS Applied Materials & Interfaces},
  year = {2025},
  doi = {10.1021/acsami.5c02812}
}
Start for free →